In the present work, we have incorporated this unnatural Tn into the most immunogenic domain of a MUC1 fragment, designing a three-component cancer vaccine (Fig. 1), similar to that previously reported by Boons and co-workers.8 We have demonstrated that the unnatural glycosylated epitope exhibits better stability in human serum when compared to the natural derivative. This evidence concerns the gene MUC1 and cancer.